CVS vs MCK: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: CVS is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CVS and MCK share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CVS and MCK exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

CVS Health runs three reporting segments. Health Care Benefits is the Aetna insurance business, which earns premiums from roughly 26 million medical members and profits when claims (the medical benefit ratio) stay below what it collects. Health Services is built around the Caremark pharmacy benefit manager, which negotiates drug prices and manages pharmacy claims for health plans and employers and generated over $48 billion of revenue in Q1 2026. Pharmacy and Consumer Wellness is the familiar retail footprint of CVS drugstores, which makes money filling prescriptions and selling front-of-store health and consumer goods, with same-store prescription volumes up nearly 7% in Q1 2026.

Full CVS guide

McKesson Corporation is a healthcare-services and pharmaceutical-distribution company, one of the "Big Three" US drug wholesalers alongside Cencora (formerly AmerisourceBergen) and Cardinal Health that together handle the large majority of prescription drugs sold in the country. In fiscal 2026 the company reported roughly $337 billion in revenue, the bulk of it from its North American Pharmaceutical segment, which sources, warehouses, and delivers branded, generic, and specialty medicines to pharmacies, health systems, and providers. Because distribution is a scale game with very low margins, McKesson competes on logistics efficiency, breadth of contracts, and reliability rather than pricing power on the drugs themselves.

Full MCK guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• CVS drivers: Integrated model under one roof; Turnaround and improving Aetna margins.
• MCK drivers: Defensive, volume-driven distribution core; Specialty and oncology services mix-shift.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The clearest risk is the medical-cost trend at Aetna: if claims reaccelerate, especially in Medicare Advantage, earnings can fall faster than premiums can be re-priced, which is what drove the 2023 to 2024 decline. For MCK, the central structural risk is razor-thin distribution margins: on hundreds of billions of revenue McKesson keeps only a small fraction as profit, so even modest cost inflation, contract losses, or generic-pricing deflation can pressure results.

Pick CVS if you believe its drivers more; MCK if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CVS and MCK guides.

CVS. CVS trades at a low forward earnings multiple versus the broad market, which reflects lingering caution after the 2023 to 2024 Aetna downturn rather than current results. The value angle rests on whether improving margins and ~$400 billion of revenue can support the raised guidance. Figures are approximate and tied to the asOf date; verify live quotes and the latest filings before acting.

MCK. All figures are approximate, tied to the asOf date, and blend fiscal-year and quarterly disclosures; verify live numbers before acting. Note McKesson reports on a fiscal year ending in March, so "fiscal 2026" spans calendar 2025 into early 2026. Because distribution revenue is enormous but low-margin, revenue-based multiples are misleading here: analysts focus on adjusted EPS growth, free cash flow, and the mix-shift toward higher-margin services.

Headline figures (approximate, 2026-06-27): CVS shows revenue (annual run-rate) ~$400 billion; FY2026 guidance at least ~$405 billion, adjusted eps (fy2026 guidance) ~$7.30 to $7.50 (Q1 2026 was ~$2.57), aetna medical benefit ratio (q1 2026) ~84.6%, improved from ~87.3% a year earlier, dividend yield ~2.5% (~$2.66 annual, ~$0.665 quarterly); MCK shows revenue (fy2026) ~$337 billion, the vast majority from North American pharmaceutical distribution (approximate; verify live), segment profit mix North American Pharmaceutical ~$3.5B adjusted operating profit; Oncology & Multispecialty ~$1.4B; Prescription Technology ~$1.1B (approximate), margin profile Very low overall (low-single-digit operating margin) because distribution dominates revenue; services segments carry much higher margins, earnings trend Management raised full-year adjusted EPS guidance multiple times through fiscal 2026 (qualitative; confirm latest figures).

CVS and MCK are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CVS and MCK exposure against your real portfolio. It is not an investment adviser.